about
Mutational profiling of kinases in glioblastoma.The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase CgammaAmplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancerInternational network of cancer genome projects.Liquid biopsies: genotyping circulating tumor DNAIntrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.PRL-3 expression in metastatic cancersIdentification of cancer genes by mutational profiling of tumor genomesInduction of epithelial tubules by growth factor HGF depends on the STAT pathwayPRL-3 phosphatase is implicated in ovarian cancer growthSpecific uncoupling of GRB2 from the Met receptor. Differential effects on transformation and motilityKRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapyActivating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemiaBRAF V600E is a determinant of sensitivity to proteasome inhibitorsToward understanding and exploiting tumor heterogeneityActivation of β-catenin by oncogenic PIK3CA and EGFR promotes resistance to glucose deprivation by inducing a strong antioxidant responseActive PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodesKRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessmentMutational analysis of gene families in human cancerDetection of circulating tumor DNA in early- and late-stage human malignanciesGab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential.Absence of AKT1 mutations in glioblastoma.Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas.A point mutation in the MET oncogene abrogates metastasis without affecting transformation.Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type.Tracking the genomic evolution of breast cancer metastasisPIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene.Mutational analysis of the tyrosine phosphatome in colorectal cancers.Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.Liquid biopsy: monitoring cancer-genetics in the blood.Kinase mutations in cancer: chinks in the enemy's armour?Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal CancerEfficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer.
P50
Q21261249-C5223DC0-D6F4-4A66-9DCD-080D84A8807CQ24310718-1135CBA1-44C7-4A1E-89F4-4A31290B44D3Q24563539-5D2F0834-533C-4D9E-845F-B8C14AF66DFDQ24611474-4DF6D92A-7ADD-4EEB-90AA-A8C5FCC79892Q27010159-77137AB3-BEA0-4DDA-A415-574E673A752CQ27852991-427CB9DF-5005-4197-8A95-5A1DBED80DBAQ27853064-004C612B-94D8-4534-B826-7D174600A791Q27853340-2EEFB44D-4A88-43C2-B975-C23374590EA1Q27853380-977B0F25-1F8D-4A94-8049-91BB62ABB0CDQ27853393-A830CC20-9362-4A2D-BC61-0D00CE74AC5FQ28189073-917533C6-60EF-45B9-9CC8-ACB9AF6445B6Q28239452-B932C352-08BF-4357-A5C1-1E9A821E7FBCQ28259695-FD8CB4A5-C374-4E4B-B66E-C0408F2AE6F3Q28275403-77F2B9B4-DF9D-416E-BF1F-B4B977E40DE4Q28281829-E6450E8F-DFD8-4344-924A-CA6D9880ACE9Q28285473-94A986FD-0AB4-4512-BCF7-39C679BA028AQ28298677-10AB35FC-3B0E-4F65-9EB0-CE3839712B13Q28300004-488E06C0-5764-434F-AEFF-146797AE3B94Q28603034-BC838DFC-1732-4DFF-9AEE-FE5542C8E263Q28729157-CE498066-8B2B-43EF-B013-7A45EE71C1D8Q28730141-47FB1A01-61EF-4AD9-892E-F792A725BBB7Q28741021-78997BA6-36F8-4189-9518-6FFB7848D98EQ29038888-27B9519F-3E26-4AF4-802D-0AF21E4AC1AAQ29615778-85BB4D25-7F15-4D54-9FD1-4757CED30E81Q30176316-42CDC7C1-85F6-4E7E-ADB3-2F358D405E61Q30439629-4B645A28-7066-45E3-8AE4-5AB0C27DD8F7Q33691544-D2588FCE-F8B7-402E-A3A4-05B8BC304549Q33731936-834F47C0-A5C0-480D-AE73-AB65E8437D9DQ33750719-83E02BA2-8450-41CC-B21E-E7ACE5497633Q33833156-6C509217-AE1E-4FDC-B300-463AB67AF4FFQ33892885-F937CB74-BA9B-4B20-8103-B0D28BE3C71CQ33933172-A6979580-CC24-45E8-BF96-FCB545BD5CABQ34094717-F0F0E37B-5DF2-4779-B3BA-3DD5FB10BFE0Q34314967-7087CF8E-EC34-4DF0-92F0-C0D906DFD176Q34322220-62446366-4086-4809-AE9D-5ADB75835BD7Q34335483-82766B00-A9BC-4D0E-A8D7-6B071B185E76Q34356149-46AA2B18-AE0F-4505-8FD3-3EC16F79F17FQ34477061-A9510ABE-F559-4963-8724-4C660FDFA017Q34501536-78DF3A71-9561-4B4C-9255-C24FF964B670Q34543264-2E611B78-201F-4CFE-8623-F1D3E174F4BD
P50
description
researcher ORCID: 0000-0003-1647-5070
@en
name
Alberto Bardelli
@ast
Alberto Bardelli
@en
Alberto Bardelli
@es
Alberto Bardelli
@nl
type
label
Alberto Bardelli
@ast
Alberto Bardelli
@en
Alberto Bardelli
@es
Alberto Bardelli
@nl
prefLabel
Alberto Bardelli
@ast
Alberto Bardelli
@en
Alberto Bardelli
@es
Alberto Bardelli
@nl
P106
P1153
7006937523
P21
P31
P496
0000-0003-1647-5070